Capricor’s regulatory odyssey for DMD cell therapy hits second FDA rejection
The FDA left Capricor Therapeutics assessing its options yet again after issuing a second rejection for the biotech’s cell therapy…
The FDA left Capricor Therapeutics assessing its options yet again after issuing a second rejection for the biotech’s cell therapy…